Given the experience of the past few years, more sponsors and CROs are incorporating DCT methods into their protocols while others are at least considering it, in part to benefit from the many advantages of DCTs as well as to avoid disruptions to future studies. While there’s no such thing as pandemic-proofing a study, building home visits into a study often is a smart choice.

If you’re like a growing number of sponsors or CROs, you already recognize the many benefits of conducting a hybrid or fully remote clinical trial. However, not all remote visit providers are the same. So how do you decide which one is right for your next trial? Start by asking the following questions and critically comparing the answers you receive.